Advancing Hemophilia Treatment through FDA Appr...

By João L. Carapinha

June 9, 2026

FDA Approval Hemophilia Treatment expands meaningful choices for people with hemophilia A and hemophilia B whose needs have long exceeded available therapies. Pfizer’s HYMPAVZI (marstacimab-hncq) now offers a once-weekly subcutaneous non-factor op...